Systemic Therapy of Cholangiocarcinoma

被引：21

作者：

Plentz, Ruben R. ^{[1
]}

Malek, Nisar P. ^{[1
]}

机构：

[1] Med Univ Hosp, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany

来源：

VISCERAL MEDICINE | 2016年 / 32卷 / 06期

关键词：

Chemotherapy; Cholangiocarcinoma; Survival; BILIARY-TRACT CANCER; PHASE-II TRIAL; INTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; 1ST-LINE TREATMENT; HER2; EXPRESSION; PLUS SORAFENIB; OPEN-LABEL; GEMCITABINE; OXALIPLATIN;

D O I：

10.1159/000453084

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Cholangiocarcinoma (CC) is the second most common primary malignant liver disease. During the last decades, various novel therapies have been introduced in the field of oncology; nevertheless, the number of treatment options for CC is still limited. Methods: In this article, current palliative chemotherapy concepts as well as new drug therapies are outlined. Results: Gemcitabine and cisplatin are the standard treatment of care for patients with inoperable CC. Second-line chemotherapy is not standardized yet and is dependent on the first-line compounds. Antibodies against VEGFR and EGFR showed mixed or negative results. New molecular systemic treatments are not established yet. Conclusion: Many clinical trials are still ongoing and new therapeutic strategies, including immunotherapies, are under active investigation. (C) 2016 S. Karger GmbH, Freiburg

引用

页码：427 / 430

页数：4

共 60 条

[51] Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany [J].

von Hahn, Thomas ;

Ciesek, Sandra ;

Wegener, Gerd ;

Plentz, Ruben R. ;

Weismueller, Tobias J. ;

Wedemeyer, Heiner ;

Manns, Michael P. ;

Greten, Tim F. ;

Malek, Nisar P. .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (09) :1092-1098

[52] Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions [J].

Voss, Jesse S. ;

Holtegaard, Leonard M. ;

Kerr, Sarah E. ;

Fritcher, Emily G. Barr ;

Roberts, Lewis R. ;

Gores, Gregory J. ;

Zhang, Jun ;

Highsmith, W. Edward ;

Hailing, Kevin C. ;

Kipp, Benjamin R. .

HUMAN PATHOLOGY, 2013, 44 (07) :1216-1222

[53] Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study [J].

Walter, Thomas ;

Horgan, Anne M. ;

McNamara, Mairead ;

McKeever, Liz ;

Min, Trisha ;

Hedley, David ;

Serra, Stefano ;

Krzyzanowska, Monika K. ;

Chen, Eric ;

Mackay, Helen ;

Feld, Ronald ;

Moore, Malcolm ;

Knox, Jennifer J. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) :329-335

[54] Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy [J].

Wang, Yizhou ;

Li, Jun ;

Xia, Yong ;

Gong, Renyan ;

Wang, Kui ;

Yan, Zhenlin ;

Wan, Xuying ;

Liu, Guanghua ;

Wu, Dong ;

Shi, Lehua ;

Lau, Wanyee ;

Wu, Mengchao ;

Shen, Feng .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) :1188-1195

[55] Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001 [J].

West, J. ;

Wood, H. ;

Logan, R. F. A. ;

Quinn, M. ;

Aithal, G. P. .

BRITISH JOURNAL OF CANCER, 2006, 94 (11) :1751-1758

[56] Characterization of EGFR family gene aberrations in cholangiocarcinoma [J].

Yang, Xiaoqing ;

Wang, Weishan ;

Wang, Chunni ;

Wang, Lin ;

Yang, Muyi ;

Qi, Mei ;

Su, Hong ;

Sun, Xiubin ;

Liu, Zhiyan ;

Zhang, Juan ;

Qin, Xiaomin ;

Han, Bo .

ONCOLOGY REPORTS, 2014, 32 (02) :700-708

[57] A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study [J].

Yi, Jun Ho ;

Thongprasert, Sumitra ;

Lee, Jeeyun ;

Doval, D. C. ;

Park, Se Hoon ;

Park, Joon Oh ;

Park, Young Suk ;

Kang, Won Ki ;

Lim, Ho Yeong .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) :196-201

[58] Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma [J].

Yoshikawa, D. ;

Ojima, H. ;

Iwasaki, M. ;

Hiraoka, N. ;

Kosuge, T. ;

Kasai, S. ;

Hirohashi, S. ;

Shibata, T. .

BRITISH JOURNAL OF CANCER, 2008, 98 (02) :418-425

[59]

Yusuf MA, 2010, J NATL COMPR CANC NE, V8, P36

[60] Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study [J].

Zhu, Andrew X. ;

Meyerhardt, Jeffrey A. ;

Blaszkowsky, Lawrence S. ;

R Kambadakone, Avinash ;

Muzikansky, Alona ;

Zheng, Hui ;

Clark, Jeffrey W. ;

Abrams, Thomas A. ;

Chan, Jennifer A. ;

Enzinger, Peter C. ;

Bhargava, Pankaj ;

Kwak, Eunice L. ;

Allen, Jill N. ;

Jain, Sanjay R. ;

Stuart, Keith ;

Horgan, Kerry ;

Sheehan, Susan ;

Fuchs, Charles S. ;

Ryan, David P. ;

Sahani, Dushyant V. .

LANCET ONCOLOGY, 2010, 11 (01) :48-54

← 1 2 3 4 5 6 →